Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Innovation / R&D category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oric Pharmaceuticals Inc. faces a significant business risk due to ongoing clinical trials by other companies involving compounds similar to their own. Reports of adverse side effects or safety concerns from these trials could hinder Oric’s ability to secure regulatory approval or successfully commercialize their products. Such developments may also damage public perception and market acceptance of Oric’s product candidates. Consequently, this risk could adversely affect the company’s business, financial condition, and operational results.
The average ORIC stock price target is $18.43, implying 87.49% upside potential.
To learn more about Oric Pharmaceuticals Inc’s risk factors, click here.